NASDAQ : SLNO

Soleno Therapeutics, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 53.01 USD (At close: May 15, 2026) · Market cap 2.76B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. As of May 18, 2026, Soleno Therapeutics, Inc. operates as a subsidiary of Neurocrine Biosciences, Inc.

Details

NameSoleno Therapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Employees182
Founded1999
Ipo Date2014-11-13
CeoAnish Bhatnagar
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS8342033094
Cusip834203200
Cik0001484565
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Dr. Anish Bhatnagar M.D.Chairman, President and Chief Executive Officer
James H. MacKanessExecutive Officer
Meredith Manning M.B.A.Chief Commercial Officer
Kevin Norrett M.B.A., M.S.Chief Business Officer
Dr. Manher A. Joshi M.D.Chief Development Officer
Jennifer FulkChief Financial Officer
Jesse SchumakerGeneral Counsel
Lauren BudesheimSenior Vice President of People
Kristen Yen M.S.Senior Vice President of Global Clinical Operations and Patient Advocacy
Dr. Neil M. Cowen M.B.A., Ph.D.Senior Vice President of New Product Planning

Contact

Address100 Marine Parkway, Suite 400, Redwood City, California 94065, United States
Phone650 213 8444
Websitehttps://soleno.life